NCT04647110View on ClinicalTrials.gov

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

CompletedOBSERVATIONAL
Enrollment

549

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

March 15, 2021

Study Completion Date

March 15, 2021

Conditions
ALK-positive NSCLC
Interventions
DRUG

crizotinib

as provided in real world practice

DRUG

alectinib

as provided in real world practice

DRUG

brigatinib

as provided in real world practice

DRUG

ceritinib

as provided in real world practice

DRUG

lorlatinib

as provided in real world practice

Trial Locations (1)

19190

Pfizer Innovations AB, Sollentuna

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04647110 - Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. | Biotech Hunter | Biotech Hunter